Bringing a companion diagnostic (CDx) to market means navigating both the complex in vitro diagnostic regulations and drug, often under tight timelines that must align with drug development milestones. With growing and more complex regulatory requirements, CDx market approval is more challenging than ever.
Cut through complexity with expert guidance. Our team provides end-to-end regulatory support tailored to your unique CDx-drug codevelopment journey. We go beyond compliance by strategically aligning your clinical, regulatory, and commercial objectives to accelerate development, reduce risk, and achieve successful CDx-drug co-approval.
